RESEARCH TRIANGLE PARK — BioAesthetics, which provides a nipple-areolar complex graft for patients undergoing breast reconstruction, has raised roughly $4.5 million, according to a recent securities filing.
Thirty-seven investors contributed to the round, which kicked off on Sept. 9. The Triangle company is still seeking to raise another $1.7 million.
The total offering amount includes $1,235,000 in convertible notes that were converted into shares pursuant to this offering, the filing noted.
BioAesthetics was founded in 2015 as a Tulane University spin-out with the mission to improve reconstruction options for breast cancer patients after they undergo mastectomies, according to Crunchbase.
It is now headquartered in RTP.
The BioAesthetics’ initial product is a tissue-engineered nipple-areolar complex (NAC). This product will be provided to plastic and reconstructive surgeons as an off-the-shelf ready, acellular, NAC graft.
During the breast reconstruction phase, after a mastectomy, the surgeon would engraft the NAC graft in position onto the patient’s reconstructed breast.
The patient’s body would then use this NAC graft as a building frame to regenerate their own NAC. This patent-pending product is currently in the pre-clinical phase.